AJP - Regu Watch the video to see how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Regul Integr Comp Physiol 284: R725-R733, 2003. First published November 14, 2002; doi:10.1152/ajpregu.00326.2002
0363-6119/03 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
284/3/R725    most recent
00326.2002v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (29)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wright, J. W.
Right arrow Articles by Harding, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wright, J. W.
Right arrow Articles by Harding, J. W.
Vol. 284, Issue 3, R725-R733, March 2003

Conversion of brain angiotensin II to angiotensin III is critical for pressor response in rats

John W. Wright1,2, Elizabeth Tamura-Myers1, Wendy L. Wilson1, Bernard P. Roques3, Catherine Llorens-Cortes4, Robert C. Speth2, and Joseph W. Harding1,2

Departments of 1 Psychology, 2 Veterinary and Comparative Anatomy, Pharmacology, and Physiology, Program in Neuroscience, Washington State University, Pullman, Washington 99164-4820; 3 Department de Pharmacochimie Moleculaire et Structurale, Institut National de la Santé et de la Recherche Médicale, Unite 266, Centre National de la Recherche Scientifique, UMR 8600, 75270 Paris, Cedex 06; and 4 Institut National de la Santé et de la Recherche Médicale, Unit 36, College de France, Chaire de Medecine Experimentale, 75005 Paris, France

The present investigation measured the relative pressor potencies of intracerebroventricularly infused ANG II, ANG III, and the metabolically resistant analogs D-Asp1ANG II and D-Arg1ANG III in alert freely moving rats. The stability of these analogs was further facilitated by pretreatment with the specific aminopeptidase A inhibitor EC33 or the aminopeptidase N inhibitor PC18. The results indicate that the maximum elevations in mean arterial pressure (MAP) were very similar for each of these compounds across the dose range 1, 10, and 100 pmol/min during a 5-min infusion period. However, D-Asp1ANG II revealed significantly extended durations of pressor effects before return to base level MAP. Pretreatment intracerebroventricular infusion with EC33 blocked the pressor activity induced by the subsequent infusion of D-Asp1ANG II, whereas EC33 had no effect on the pressor response to subsequent infusion of D-Arg1ANG III. In contrast, pretreatment infusion with PC18 extended the duration of the D-Asp1ANG II pressor effect by about two to three times and the duration of D-Arg1ANG III's effect by ~10 to 15 times. Pretreatment with the specific AT1 receptor antagonist losartan blocked the pressor responses induced by the subsequent infusion of both analogs indicating that they act via the AT1 receptor subtype. These results suggest that the brain AT1 receptor may be designed to preferentially respond to ANG III, and ANG III's importance as a centrally active ligand has been underestimated.

blood pressure; D-Asp1Angiotensin II; D-Arg1Angiotensin III


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
B. S. Huang, M. Ahmad, J. Tan, and F. H. H. Leenen
Chronic central versus systemic blockade of AT1 receptors and cardiac dysfunction in rats post-myocardial infarction
Am J Physiol Heart Circ Physiol, September 1, 2009; 297(3): H968 - H975.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
L. Bodineau, A. Frugiere, Y. Marc, N. Inguimbert, C. Fassot, F. Balavoine, B. Roques, and C. Llorens-Cortes
Orally Active Aminopeptidase A Inhibitors Reduce Blood Pressure: A New Strategy for Treating Hypertension
Hypertension, May 1, 2008; 51(5): 1318 - 1325.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
S. H. Padia, B. A. Kemp, N. L. Howell, M.-C. Fournie-Zaluski, B. P. Roques, and R. M. Carey
Conversion of Renal Angiotensin II to Angiotensin III Is Critical for AT2 Receptor-Mediated Natriuresis In Rats
Hypertension, February 1, 2008; 51(2): 460 - 465.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
R. J. Kokje, W. L. Wilson, T. E. Brown, V. T. Karamyan, J. W. Wright, and R. C. Speth
Central Pressor Actions of Aminopeptidase-Resistant Angiotensin II Analogs: Challenging the Angiotensin III Hypothesis
Hypertension, June 1, 2007; 49(6): 1328 - 1335.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
S. H. Padia, B. A. Kemp, N. L. Howell, H. M. Siragy, M.-C. Fournie-Zaluski, B. P. Roques, and R. M. Carey
Intrarenal Aminopeptidase N Inhibition Augments Natriuretic Responses to Angiotensin III in Angiotensin Type 1 Receptor-Blocked Rats
Hypertension, March 1, 2007; 49(3): 625 - 630.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
S. H. Padia, N. L. Howell, H. M. Siragy, and R. M. Carey
Renal Angiotensin Type 2 Receptors Mediate Natriuresis Via Angiotensin III in the Angiotensin II Type 1 Receptor-Blocked Rat
Hypertension, March 1, 2006; 47(3): 537 - 544.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online